Ultrasonic contrast agent loaded with therapeutic drug and preparation method thereof
A technology of ultrasound contrast agents and therapeutic drugs, which is applied in echo/ultrasound imaging agents, drug combinations, and pharmaceutical formulations, etc. It can solve problems such as side effects of ultrasound therapy, large ultrasound doses, and hemolysis in the heart chamber, and reduce side effects on the human body. Ensure safe use and avoid side effects
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0041] This embodiment relates to a group of ultrasound contrast agents loaded with therapeutic drugs, and the raw material components of the contrast agents are shown in the following table:
[0042]
[0043]
[0044]
[0045] The raw material components in the above table are prepared according to the following steps:
[0046] a. Preparation of targeted polymerized phospholipids: four-arm or multi-arm-N-hydroxysuccinimide succinate-based polyethylene glycol, and polypeptide, dipalmitoylphosphatidylethanolamine, or four-arm or multi-arm Arm-N-hydroxysuccinimide succinate-based polyethylene glycol, polypeptide, distearoyl phosphatidylethanolamine, physically mixed evenly, using disodium bicarbonate and sodium dihydrogen carbonate to adjust the mixed solution to The alkaline condition of pH 8.0~10.0 makes the electrophilic group-NHS of PEG derivatives, and the nucleophilic group-NH 2 , to carry out covalent binding to obtain polymerized phospholipids containing ligand...
Embodiment 2
[0056] This example relates to the influence of factors such as the selection of film-forming phospholipid raw materials and contrast agent preparation conditions on the performance of the ultrasound contrast agent of the present invention.
Embodiment 21
[0058] This embodiment involves the influence of film-forming phospholipid raw materials on the ultrasonic cavitation frequency performance of the obtained ultrasonic contrast agent. Different film-forming phospholipid raw materials are used, and other raw materials and preparation conditions are the same for comparison. The results are shown in the following table:
[0059]
[0060] It can be seen from the results in the above table that the film-forming phospholipid selected in the present invention can significantly reduce the ultrasonic cavitation frequency of the ultrasonic contrast agent, which is beneficial to the safety of use.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


